|
|
|
|
|
|
|
|
|
22.07.26 - 07:48
|
Pharma stocks bleed after Trump announces upto 200% tariff on generic drugs (Times of India)
|
|
|
Pharmaceutical stocks faced pressure after US President Trump unveiled a phased tariff plan for imported generic medicines. This plan introduces steep duties on generic drugs after a two-year tariff-free window. Indian drugmakers are reassessing supply chains and investment plans due to potential future impacts. Companies without US manufacturing presence may face significantly altered economics. The announcement shifts focus to encouraging domestic production within the United States....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.07.26 - 13:00
|
US biotech firm developing therapies for infant brain injuries plans Hong Kong listing (SCMP)
|
|
|
A US-headquartered biotech firm plans to seek a primary listing in Hong Kong, joining a swelling pipeline of artificial intelligence-powered medical players raising capital in the city.
Axiom Biosciences, which develops experimental therapies for newborns with severe brain injuries by using AI, is targeting at least US$200 million through an initial public offering (IPO) in Hong Kong in 2027, followed by a secondary listing in the US in 2029.
“Some of the most important science in the world is......
|
|
|
|
|
|
|
|
|
|
|
|
|
|